07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

AV0113 regulatory update

FDA granted Orphan Drug designation to AV0113 to treat malignant glioma. The dendritic cell-based cancer immunotherapy has Orphan Drug designation in the EU to treat glioma. AV0113 is Phase II testing to treat glioblastoma multiforme...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

AV0113: Preliminary Phase II data

Activartis reported preliminary data from the open-label, Austrian Phase II GBM-Vax trial in about 100 brain cancer patients aged 18-70 years showing that AV0113 administered into inguinal lymph nodes as an add-on to standard therapy...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

AV0113 regulatory update

EMA granted Orphan Drug designation for Activartis' AV0113 to treat glioma. The dendritic cell cancer vaccine is in Phase II testing to treat glioblastoma multiforme (GBM). Activartis Biotech GmbH , Vienna, Austria   Product: AV0113...